News & Views

News and Opinions


Antibiotics in wastewater from pharmaceutical companies: Where are we at?

Over the last years pharmaceutical companies made commitments for change and curbing antibiotic waste has been voiced as one of their top priorities. This year we grab the opportunity at World Water Day to look where we are at now: Have pharmaceutical companies taken action on their own commitments? And how are governments tackling this issue?


Unavailability of old antibiotics is threatening effective treatment of common bacterial infections

In a commentary in The Lancet Infectious Diseases, leading experts from ReAct and other key stakeholder groups discuss the increasing problem with lack of availability of essential antibiotics.



Why are fixed dose combinations of antibiotics generally not a good idea?

Fixed dose combinations are pharmaceutical products such as tablets, ointments or suspensions where two or more antibiotics are combined in one product. In the treatment of Tuberculosis and HIV, they are vital for treatment success as they improve compliance and reduce development of resistance. In theory, it sounds like a good idea to copy this success to other bacteria and antibiotic resistance, but in practice it is generally not so.


New expert advisory group for the ReAct Toolbox

ReAct is very glad to announce the establishment of an expert advisory group for our web-based Toolbox for action on antibiotic resistance. The advisory group is composed of renowned experts from the antibiotic resistance field.


ReAct reflections on the Prince Mahidol Award Conference and the IACG Civil Society Engagement Panel

Given the strong emphasis on antimicrobial resistance, several people from ReAct joined the conference and discussions on sustainable solutions to contain antibiotic resistance. Antimicrobial resistance was at the top of the agenda, and for the first time at a high-level conference prominently discussed as an emerging infectious disease.


From the Regional Stakeholders’ Summit in Cape Town: 4 needs to address so diagnostics can help contain antimicrobial resistance

How can diagnostics contribute to contain antimicrobial resistance? That was the main question during the Regional Stakeholders’ Summit in Cape Town end January. ReAct Africa has summarized a list of the most mentioned needs that need to be attended to.


4 take aways from the newly published GLASS report

End January, the first report from the WHO Global Antimicrobial Resistance Surveillance System (GLASS) was released. ReAct summarizes 4 take aways from the report.


ReAct responds to final report from DRIVE-AB

The DRIVE-AB consortium has worked to develop recommendations on how to change the innovation system to revitalize the antibiotic pipeline, while ensuring sustainable use and access. Now it published their final report. Anna Zorzet, Head of ReAct Europe, says:

“Ensuring affordable and sustainable access to new antibiotics without risking excess in all countries should be at the crux of the R&D financing discussions – not placed as an afterthought.”


WHO proposes new sepsis target to guide work and actions on antibiotic resistance

January 22-27, the WHO will hold its 142nd meeting of the Executive Board in Geneva. The discussions are likely to be dominated by the draft General Work Program for 2019-2023. A new target on reducing sepsis cases by 10% is introduced as a benchmark for the field of antibiotic resistance.


Antibiotic resistance on agenda for The Prince Mahidol Award Conference: A policy stage led by low and middle income countries

Under the theme “Making the World Safe from the Threats of Emerging Infectious Diseases”, this year’s Prince Mahidol Award Conference (PMAC) 2018 will give the challenge of antibiotic resistance prominent attention. ReAct will have several people attending the conference to present and engage in the discussions.


Joint letter to IACG on AMR: A call to increase transparency and civil society involvement

ReAct, together with other members of the Antibiotic Resistance Coalition (ARC) has written a joint letter to the UN Inter-Agency Coordination Group (IACG) on Antimicrobial Resistance to call on the group to increase the transparency of, and civil society involvement in, its policy deliberation and meeting process.


Costing National Action Plans on AMR: Practical suggestions for simplifying the process

Costing a country’s National Action Plan on AMR appears to be a daunting and challenging task. As Dr. Kim Faure has great experience on costing National Action Plans on AMR ReAct interviewed her to help countries with som practical steps in the process.


ReAct wishes for 2018 – node by node

We would like to thank you for 2017 with wishes for an exciting 2018!

Here you find ReAct wishes for 2018, node by node. Together we can make a difference.